spot_img
Tuesday, December 10, 2024
HomeMarkets NewsCaplin Point shares hit 52-week high after US FDA’s EIR to its...

Caplin Point shares hit 52-week high after US FDA’s EIR to its subsidiary

-


Shares of Caplin Point Laboratories Ltd rallied 5 per cent to hit a 52-week high of ₹1,121.60 on the National Stock Exchange (NSE) on Tuesday. The rally came a day after a subsidiary of the Chennai-based pharmaceutical company received an establishment inspection report (EIR) for one of its units. 

On Monday, Caplin Point announced that the US Food and Drug Administration (USFDA) has issued an EIR for an injectable and ophthalmic manufacturing unit of its subsidiary, Caplin Sterlies. The company said this is the fourth USFDA audit at the site and the company has received the EIR with a satisfactory outcome. 

Shares of Caplin Point opened at ₹1,075 and touched an intraday and 52-week high of ₹1,121.60 before closing at ₹1,117 on the NSE.





Source link

Related articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
3,912FollowersFollow
0SubscribersSubscribe
Trump campaign reports raising more than  million after Georgia booking

Latest posts